서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 30 of 30

Issue DateTitle / Author(s) / CitationFileAltmetrics
2004-02
Transforming growth factor-β1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells
DOI
2005-08
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor
DOI
2006-04
Immunological synapse arrays: Patterned protein surfaces that modulate immunological synapse structure formation in T cells

Doh, J; Irvine, DJ

Proceedings of the National Academy of Sciences of the United States of America, Vol.103 No.15, pp.5700-5705

DOI
2008-01
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
DOI
2008-03
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Kim, Hwang-Phill; Han, Sae-Won; Kim, Sung-Hak; Im, Seock-Ah; Oh, Do-Youn; Bang, Yung-Jue; Kim, Tae-You

Molecular Cancer Therapeutics, Vol.7 No.3, pp.607-615

DOI
2009-05
Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer
DOI
2010-03
Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43
DOI
2010-10
How to Overcome Retinal Neuropathy: The Fight against Angiogenesis-related Blindness

Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun

Archives of Pharmacal Research, Vol.33 No.10, pp.1557-1565

DOI
2011-11
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

Kim, Min A.; Lee, Hyuk-Joon; Yang, Han-Kwang; Bang, Yung-Jue; Kim, Woo Ho

Histopathology, Vol.59 No.5, pp.822-831

DOI
2012-01
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
DOI
2012-02
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
DOI
2012-03
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells
DOI
2012-03
Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody
DOI
2012-09
Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer

Bang, Yung-Jue

Journal of Clinical Gastroenterology, Vol.46 No.8, pp.637-648

DOI
2014-12
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
DOI
2016-02
WNT signaling in glioblastoma and therapeutic opportunities

Lee, Yeri; Lee, Jin-Ku; Ahn, Sun Hee; Lee, Jeongwu; Nam, Do-Hyun

Laboratory Investigation, Vol.96 No.2, pp.137-150

DOI
2016-03
Substitution of heavy complementarity determining region 3 (CDR-H3) residues can synergistically enhance functional activity of antibody and its binding affinity to HER2 antigen
view fileDOI
2016-07
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors
DOI
2017-01
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-O13/LOGiC Trial of Lapatinib
DOI
2018-01
Pre-clinical results in pig-to-non-human primate islet xenotransplantation using anti-CD40 antibody (2C10R4)-based immunosuppression
DOI
2018-02
Challenges and opportunities in biopharmaceutical manufacturing control

Hong, Moo Sun; Severson, Kristen A.; Jiang, Mo; Lu, Amos E.; Love, J. Christopher; Braatz, Richard D.

COMPUTERS & CHEMICAL ENGINEERING, Vol.110, pp.106-114

DOI
2018-03
Long-term trastuzumab (Herceptin (R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
view fileDOI
2019-02
Bispecific anti-mPDGFR beta x cotinine scFv-C-kappa-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR beta expressing cells
DOI
2019-06
Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea
view fileDOI
2019-09
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
DOI
2019-11
An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence
DOI
2020-01
HER2-targeted therapies - a role beyond breast cancer

Oh, Do-Youn; Bang, Yung-Jue

Nature Reviews Clinical Oncology, Vol.17 No.1, pp.33-48

DOI
2021-04
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
DOI
2021-08
The 'cytokine storm': molecular mechanisms and therapeutic prospects

Karki, Rajendra; Kanneganti, Thirumala-Devi

Trends in Immunology, Vol.42 No.8, pp.681-705

DOI
2023-04
Anti-Alpha-Toxin Antibody Responses and Clinical Outcomes of Staphylococcus aureus Bacteremia
DOI
1